ArticleBMC cancer2026
Expression of p16 and p53 proteins in cervical cancer cases in a tertiary centre in Ghana: an immunohistochemical study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer remains a major public health concern in Ghana, with limited screening coverage and late-stage presentation. Biomarkers such as p16 and p53 have been explored for their diagnostic and prognostic relevance in cervical cancer. The study aims to elucidate the possibility of using p16 immunohistochemistry as a surrogate marker for HPV infection in cervical cancer among other things and role of p53 in cervical cancer.
methodsA retrospective descriptive study was conducted on 135 Formalin-Fixed-Paraffin-Embedded archived cervical tissue samples at a tertiary facility in Kumasi, Ghana. Histological evaluation and immunohistochemical staining for p16 and p53 were performed. Data were analysed using SPSS with associations between biomarker expression and clinicopathological variables (age, histological type, tumour grade) assessed.
resultsThe age range of the participants was 31-115 year with a mean age of 58.93 ± 17.88 years. Most cases (96.3%) were squamous cell carcinoma, with 49.6% being poorly differentiated. p16 was positively expressed in 71.11% of cases, while p53 showed 63.70% positivity. Significant associations were observed between p16 and tumour grade (p = 0.02), and between p53 and histological type (p = 0.021). No significant correlations were found between marker expression and age (p = 0.174).
conclusionThe high expression of p16 and p53, particularly in squamous and high-grade lesions, shows their potential role in early detection and prognostication of cervical cancer. These biomarkers may serve as cost-effective tools in resource-limited settings like Ghana, supporting improved clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.